Business Context and Reporting Period
SciSparc Ltd., a foreign private issuer based in Tel Aviv, Israel, filed Form 6-K on February 27, 2024. The report covers the month of February 2024 and primarily serves to disseminate a press release regarding intellectual property developments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The material change reported is the issuance of a press release on February 27, 2024, announcing a partnership with Clearmind. This collaboration has resulted in three new international patent applications covering compounds related to MDMA, Ibogaine, and Ketamine.
Guidance, Outlook, and Risks
The filing incorporates the press release by reference into the Company's registration statements on Form F-3 and Form S-8. No specific financial guidance, management commentary on future performance, or explicit risk factors are detailed within the text of this specific Form 6-K.
Investor Verification Checklist
- Verify the details of the three new international patent applications for MDMA, Ibogaine, and Ketamine compounds.
- Review the full text of the press release furnished as Exhibit 99.1 for partnership terms with Clearmind.
- Confirm the status of the Company's registration statements (Form F-3 and Form S-8) where this information is incorporated.